185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation

Autor:	J. Chmiel, P.J. Barry, C. Colombo, E. De Wachter, I. Fajac, M. Mall, K. McBennett, E. McKone, P. Mondejar-Lopez, B. Quon, B. Ramsey, P. Robinson, S. Sutharsan, N. Ahluwalia, M. Lu, S. Moskowitz, V. Prieto-Centurion, S. Tian, D. Waltz, T. Weinstock, F. Xuan, L. Zelazoski, Y. Zhang, D. Polineni
Rok vydání:	2022
Předmět:	Pulmonary and Respiratory Medicine Pediatrics Perinatology and Child Health
Zdroj:	Journal of Cystic Fibrosis. 21:S108-S109
ISSN:	1569-1993
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bc767058b1c6a42ab65c8fe1dbd43e1a https://doi.org/10.1016/s1569-1993(22)00875-x Zobrazit plný text záznamu Full Text from ScienceDirect